echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In 2022, the merger and acquisition boom of chain pharmacies will continue!

    In 2022, the merger and acquisition boom of chain pharmacies will continue!

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, with the advancement of policies such as prescription outflow, public hospital reform, medical insurance fee control, centralized procurement, and "dual-channel" policies, the domestic pharmaceutical retail industry has accelerated its reshuffle
    .
    Compared with single pharmacies, large chain pharmacies are more capable of taking on challenges and have more survival experience
    .
    Entering 2022, the upsurge of mergers and acquisitions in chain pharmacies will continue.
    In just three months, many pharmaceutical companies have reported mergers and acquisitions
    .
    The common people announced on the evening of March 6 that they planned to acquire about 71.
    96% of the shares of Huairen Great Health held by 14 counterparties including Lin Chengxiong and Chen Yuping for 1.
    637 billion yuan
    .
    According to the data, Huairen Great Health is a large-scale enterprise spanning the chain pharmacy area in Hunan and Guizhou.
    It has more than 660 self-operated pharmacies in Hunan and Guizhou
    .
    Before the completion of this transaction, the common people held about 4.
    16% of the equity of Huairen Great Health.
    After the acquisition of Huairen Great Health, the common people will hold more than 76% of the shares of Huairen Great Health
    .
    Its market share in Hunan and Guizhou is also expected to be further enhanced, enhancing its voice in these regions
    .
    It is understood that after the completion of this transaction, the number of ordinary people's stores in Hunan Province is expected to exceed 3,000 (including franchisees), and the number of regional stores in Hunan Province will rank first
    .
    At the same time, the people will further increase the scale of procurement and reduce procurement costs
    .
    According to the news disclosed at the 2020 General Meeting of Shareholders by Common People Pharmacy, the common people will maintain the rhythm of rapid store opening in the next two years, in order to drive the company's future performance to grow steadily
    .
    According to the three-year plan proposed by the common people in 2019, 2,000 new stores will be added every year until 2022
    .
    Looking at it now, the common people have made a decision on major mergers and acquisitions at the beginning of the year, which can be described as a compact layout
    .
    The third quarterly report of 2021 shows that in the first three quarters, there were 1,866 new stores for ordinary people, and the acceleration trend was obvious
    .
    The company said that it will retain part of the original founder's equity, and the group headquarters will acquire regional giants through the "Spark" model, so as to achieve cross-provincial expansion and deep cultivation of advantageous markets.
    Rate
    .
    In addition to ordinary people, on February 28, Yunnan Jianzhijia also issued an announcement on planning major asset restructuring and signing an agreement of intent for equity acquisition
    .
    The announcement stated that it intends to acquire 80%-100% of the shares of Tangren Pharmaceutical held by the shareholders of Hebei Tangren Pharmaceutical after the reorganization by paying cash
    .
    It is understood that Hebei Tangren Pharmaceutical involves about 660 stores, of which the stores in Hebei Province are mainly located in Tangshan and Qinhuangdao, which are the largest chain pharmacies in the two regions
    .
    Through this acquisition, the common people will realize the acquisition of Tangren Pharmaceutical chain pharmacy brand and directly-operated stores, various operating assets, operating resources and operating rights and interests, and promote the company's business expansion in the Bohai Rim region with Beijing-Tianjin-Hebei as the core
    .
    It is reported that if the acquisition is successful, Yunnan Jianzhijia will become the third case of the provincial head chain merged into a national chain in Hebei Province after Yifeng Pharmacy and Common People
    .
    According to incomplete statistics, in the past year, Jianzhijia has spent nearly 200 million yuan to acquire 157 pharmacies.
    The third quarter report of 2021 shows that as of September 2021, Jianzhijia’s total number of stores may exceed 2,600
    .
    2022 has just started for three months.
    Which chain pharmacy giants will be involved in mergers and acquisitions, and which pharmacies will be acquired or eliminated.
    Let’s pay attention to the next trends in the pharmaceutical retail industry! Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.